Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Physical Activity and Mortality in Patients With Stable Coronary Heart Disease.
Stewart RAH, Held C, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, Hagström E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG, Vedin O, Wallentin L, White HD; STABILITY Investigators. Stewart RAH, et al. Among authors: nicolau jc. J Am Coll Cardiol. 2017 Oct 3;70(14):1689-1700. doi: 10.1016/j.jacc.2017.08.017. J Am Coll Cardiol. 2017. PMID: 28958324 Free article. Clinical Trial.
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW; COMMA Investigators. Granger CB, et al. Among authors: nicolau jc. Circulation. 2003 Sep 9;108(10):1184-90. doi: 10.1161/01.CIR.0000087447.12918.85. Epub 2003 Aug 18. Circulation. 2003. PMID: 12925454 Clinical Trial.
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, Armstrong PW; COMPLY Investigators. Mahaffey KW, et al. Among authors: nicolau jc. Circulation. 2003 Sep 9;108(10):1176-83. doi: 10.1161/01.CIR.0000087404.53661.F8. Epub 2003 Aug 18. Circulation. 2003. PMID: 12925455 Clinical Trial.
Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial).
Patel MR, Mahaffey KW, Armstrong PW, Weaver WD, Tasissa G, Hochman JS, Todaro TG, Malloy KJ, Rollins S, Theroux P, Ruzyllo W, Nicolau JC, Granger CB; CARDINAL Investigators. Patel MR, et al. Among authors: nicolau jc. Am J Cardiol. 2005 Mar 1;95(5):614-8. doi: 10.1016/j.amjcard.2004.11.008. Am J Cardiol. 2005. PMID: 15721102 Clinical Trial.
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
Théroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, Nicolau JC, Lavoie J, Luong TM, Burchenal J, Granger CB. Théroux P, et al. Among authors: nicolau jc. Eur Heart J. 2005 Oct;26(19):1964-70. doi: 10.1093/eurheartj/ehi292. Epub 2005 May 4. Eur Heart J. 2005. PMID: 15872036 Clinical Trial.
Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil.
Lopes RD, Becker RC, Garcia D, Hylek EM, Granger CB, Lourenço DM, Nader HB, Maffei FH, Cesena FH, Nicolau JC, Timmerman A, Rocha AT, de Paiva EF, Guimaraes HP, Carvalho AC, D'Amico EA, Moreira-Filho CA, Aldrighi JM, Lopes AC. Lopes RD, et al. Among authors: nicolau jc. J Thromb Thrombolysis. 2009 Jul;28(1):106-16. doi: 10.1007/s11239-009-0324-4. Epub 2009 Mar 26. J Thromb Thrombolysis. 2009. PMID: 19322521 Review.
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E. Morrow DA, et al. Among authors: nicolau jc. Circulation. 2009 Jun 2;119(21):2758-64. doi: 10.1161/CIRCULATIONAHA.108.833665. Epub 2009 May 18. Circulation. 2009. PMID: 19451347 Clinical Trial.
319 results